Literature DB >> 16295030

Influence of recent advances in medical management on clinical outcomes of cirrhosis.

Jayant A Talwalkar1, Patrick S Kamath.   

Abstract

Cirrhosis and its disease-related complications are the 12th leading cause of mortality among U.S. adults and are the 5th leading cause of death for individuals aged 45 to 54 years. Hospitalization costs for disease-related complications are estimated at 18,000 dollars per episode of care, and 10% of admitted patients die. Despite these ominous findings, the survival rate of patients with cirrhosis has improved during the past 2 decades. This observation coincides with the conducting and reporting of high-quality randomized controlled trials and observational studies. Therefore, the improved prognosis in cirrhosis may be related to the effective translation of research findings to clinical practice for this patient population. Although explicit data to support this claim are not available, this article reviews the reported trends in clinical outcomes for patients with cirrhosis and the existence of evidence-based medical information that is available to care for these chronically ill patients.

Entities:  

Mesh:

Year:  2005        PMID: 16295030     DOI: 10.4065/80.11.1501

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  17 in total

1.  Hemodynamic effects of renin-angiotensin-aldosterone inhibitor and β-blocker combination therapy vs. β-blocker monotherapy for portal hypertension in cirrhosis: A meta-analysis.

Authors:  Jianrong Wang; Wenxia Lu; Jingjing Li; Rong Zhang; Yuqing Zhou; Qin Yin; Yuanyuan Zheng; Fan Wang; Yujing Xia; Kan Chen; Sainan Li; Tong Liu; Jie Lu; Yingqun Zhou; Chuan-Yong Guo
Journal:  Exp Ther Med       Date:  2017-03-09       Impact factor: 2.447

2.  PROMIS computerised adaptive tests are dynamic instruments to measure health-related quality of life in patients with cirrhosis.

Authors:  J S Bajaj; L R Thacker; J B Wade; A J Sanyal; D M Heuman; R K Sterling; D P Gibson; R T Stravitz; P Puri; M Fuchs; V Luketic; N Noble; M White; D Bell; D A Revicki
Journal:  Aliment Pharmacol Ther       Date:  2011-09-19       Impact factor: 8.171

3.  Application of the Intermediate-Stage Subclassification to Patients With Untreated Hepatocellular Carcinoma.

Authors:  Edoardo G Giannini; Alessandro Moscatelli; Gaia Pellegatta; Alessandro Vitale; Fabio Farinati; Francesca Ciccarese; Fabio Piscaglia; Gian Lodovico Rapaccini; Maria Di Marco; Eugenio Caturelli; Marco Zoli; Franco Borzio; Giuseppe Cabibbo; Martina Felder; Rodolfo Sacco; Filomena Morisco; Gabriele Missale; Francesco Giuseppe Foschi; Antonio Gasbarrini; Gianluca Svegliati Baroni; Roberto Virdone; Alberto Masotto; Franco Trevisani
Journal:  Am J Gastroenterol       Date:  2016-01-05       Impact factor: 10.864

Review 4.  Mechanisms, diagnosis and management of hepatic encephalopathy.

Authors:  Ravi Prakash; Kevin D Mullen
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-08-10       Impact factor: 46.802

5.  Liver stiffness measurement by magnetic resonance elastography is not associated with developing hepatocellular carcinoma in subjects with compensated cirrhosis.

Authors:  R Anaparthy; J A Talwalkar; M Yin; L R Roberts; J L Fidler; R L Ehman
Journal:  Aliment Pharmacol Ther       Date:  2011-05-03       Impact factor: 8.171

6.  Driving Performance Among Patients with Cirrhosis Who Drove to Their Outpatient Hepatology Clinic Appointments.

Authors:  Paul J Thuluvath; Anantha Nuthalapati; Jennifer Price; Anurag Maheshwari
Journal:  J Clin Exp Hepatol       Date:  2015-10-03

7.  Incidence, prevalence, and clinical significance of abnormal hematologic indices in compensated cirrhosis.

Authors:  Amir A Qamar; Norman D Grace; Roberto J Groszmann; Guadalupe Garcia-Tsao; Jaime Bosch; Andrew K Burroughs; Cristina Ripoll; Rie Maurer; Ramon Planas; Angels Escorsell; Juan Carlos Garcia-Pagan; David Patch; Daniel S Matloff; Robert Makuch; Gabriel Rendon
Journal:  Clin Gastroenterol Hepatol       Date:  2009-03-10       Impact factor: 11.382

Review 8.  Magnetic resonance elastography (MRE) in cancer: Technique, analysis, and applications.

Authors:  Kay M Pepin; Richard L Ehman; Kiaran P McGee
Journal:  Prog Nucl Magn Reson Spectrosc       Date:  2015-06-23       Impact factor: 9.795

9.  Minimal hepatic encephalopathy matters in daily life.

Authors:  Jasmohan S Bajaj
Journal:  World J Gastroenterol       Date:  2008-06-21       Impact factor: 5.742

10.  Conventional predictors of survival poorly predict and significantly underpredict survival after H-graft portacaval shunts.

Authors:  Sarah M Cowgill; Donald Thometz; Whalen Clark; Desiree Villadolid; Elizabeth Carey; Daphne Pinkas; Emmanuel Zervos; Alexander Rosemurgy
Journal:  J Gastrointest Surg       Date:  2007-01       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.